Related Experiment Video
Updated: Feb 28, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
14.0K
Cell-surface targets for prostate cancer therapeutics.
Samuel Ruder1, Pardis Ziaeefar2, Ambika P Jaswal3
1Department of Medicine, Division of Hematology and Oncology, New York Presbyterian Weill Cornell Medical Center, New York, NY.
Urologic Oncology
|February 25, 2026
Summary
New prostate cancer therapeutics target cell surface antigens. Research reviews clinical data on antigens like PSMA and TROP-2, crucial for developing effective treatments.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Prostate cancer treatment requires novel therapeutic targets.
- Cell surface antigens on cancer cells and tumor microenvironment offer potential targets.
- Understanding antigen expression is key for targeted therapies.
Purpose of the Study:
- To review recent clinical data on cell surface antigens in prostate cancer.
- To describe the biological role and expression patterns of these antigens.
- To evaluate their potential as targets for novel therapeutics.
Main Methods:
- Review of clinical data from human subjects.
- Analysis of histological and genomic data for antigen expression.
- Quantitative assessment using targeted immuno-PET where available.
Main Results:
- Specific antigens (PSMA, TROP-2, STEAP1, PSCA) are overexpressed in prostate adenocarcinoma.
- CEACAM5 and DLL3 are more common in neuroendocrine prostate cancer.
- CD46 expression is noted in both subtypes; HER2 relevance is unclear; FAP is found on cancer-associated fibroblasts.
Conclusions:
- Promising cell surface antigens are identified for prostate cancer treatment.
- Expression patterns vary by histologic type, location, and treatment status.
- These factors will influence the development and utility of new therapeutic agents.
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:26Targets for Drug Action: Overview
10.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.8K
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.5K
02:38Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K